William A. Haseltine - 12 Nov 2021 Form 4 Insider Report for Acasti Pharma Inc. (GRCE)

Reporting relationship: Director
Issuer ticker: GRCE
Reported as of: 12 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Nov 2021, 15:19:31 UTC
Prior SEC filing: 03 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Jason Comerford, attorney-in fact for Mr.Haseltine

Key filing fact

William A. Haseltine filed Form 4 for Acasti Pharma Inc. (GRCE) on 16 Nov 2021.

Key facts

This page summarizes William A. Haseltine's Form 4 filing for Acasti Pharma Inc. (GRCE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Nov 2021, 15:19.

Change

Previous filing in this sequence was filed on 03 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACST transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +42,100
Change %
Price: $0.000000
Shares after: 42,100
Date: 12 Nov 2021
Ownership: Direct
Underlying class: Class A Common Shares
Underlying amount: 42,100
Exercise price: $1.63
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant.

Footnote F2

Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months.